David Dolphin, a professor of chemistry at the University of British Columbia, has conducted groundbreaking research that has resulted in pharmaceutical innovations. Chief among them is Visudyne, a treatment for a type of age-related macular degeneration that can lead to blindness. As an executive with Quadra Logic Technology, he has played a key role in the commercialization of this discovery. He has also contributed to the wider scientific community through his leadership of Genome British Columbia and the BC Innovation Council. Throughout his career, he has championed the transfer of technology and intellectual property from the university laboratory to the marketplace.